|
1.
|
Kleihues P, Louis DN, Scheithauer BW,
Rorke LB, Reifenberger G, Burger PC and Cavanee WK: The WHO
classification of tumors of the nervous system. J Neuropathol Exp
Neurol. 6:215–225. 2002.
|
|
2.
|
Lois DN, Ohgaki H, Wiestler OD and Cavanee
WK: WHO Classification of Tumors of the Central Nervous System.
IARC; Lyon: 2007
|
|
3.
|
Birlik B, Canda S and Ozer E: Tumour
vascularity is of prognostic significance in adult, but not
paediatric astrocytomas. Neuropathol Appl Neurobiol. 32:532–538.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Weidner N, Semple JP, Welch WR and Folkman
J: Tumor angiogenesis and metastasis – correlation in invasive
breast carcinoma. N Eng J Med. 324:1–8. 1991.
|
|
5.
|
Tanaka F, Otake Y, Yanagihara K, et al:
Evaluation of angiogenesis in non-small cell lung cancer:
Comparison between anti-CD34 antibody and anti-CD105 antibody. Clin
Cancer Res. 7:3410–3415. 2001.PubMed/NCBI
|
|
6.
|
Offersen B, Pfeiffer P, Hamilton-Dutoit S
and Overgaad J: Patterns of angiogenesis in non-small cell lung
carcinoma. Cancer. 91:1500–1509. 2001. View Article : Google Scholar
|
|
7.
|
Ding S, Li C, Lin S, et al: Comparative
evaluation of microvessel density determined by CD34 or CD105 in
benign and malignant gastric lesions. Hum Pathol. 37:861–866. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Amar A, Giovanini AF, Rosa MP, Yamassaki
HO, De Carvalho MB and Rapoport A: Densidade microvascular no
carcinoma de língua. Rev Assoc Med Bras. 48:204–208. 2002.
|
|
9.
|
Leon SP, Folkerth RD and Black PM:
Microvessel density is a prognostic indicator for patients with
astroglial brain tumors. Cancer. 77:362–372. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Yao Y, Kubota T, Takeuchi H and Sato K:
Prognostic significance of microvessel density determined by an
anti-CD105/endoglin monoclonal antibody in astrocytic tumors:
comparison with an anti-CD31 monoclonal antibody. Neuropathology.
25:201–206. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Baldari S, Pecorella R, Cosentino S and
Minutoli F: Investigation of brain tumours with 99mTc-MIBI SPECT. Q
J Nucl Med. 46:336–345. 2002.PubMed/NCBI
|
|
12.
|
Goethals I, De Winter O, Dierckk R,
Annovazzi A, Signore A and van de Wiele C: False-negative Tc-99m
scintigraphy in histopathologically proved recurrent high-grade
oligodendroglioma. Clin Nucl Med. 28:299–301. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Minutoli F, Angileri FF, Conti A, et al:
Timing of examination affects reliability of
99mTc-methoxyisobutylisonitrile SPECT in distinguishing neoplastic
from nonneoplastic brain hematomas. J Nucl Med. 46:574–579.
2005.
|
|
14.
|
Andrews DW, Das R, Kim S, Zhang J and
Curtis M: Technetium-MIBI as a glioma imaging agent for the
assessment of multidrug resistance. Neurosurgery. 40:1323–1332.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Sasajima T, Shimada N, Naitoh Y, Takahashi
M, Hu Y, Satohh T and Mizoi K: 99mTc-MIBI imaging for prediction of
therapeutic effects of second-generation MDR1 inhibitors in
malignant brain tumors. Int J Cancer. 121:2637–2645. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Staudenherz A, Fazeny B, Marosi C, et al:
Does 99mTc-sestamibi in high-grade malignant brain tumors reflect
blood-brain barrier damage only? Neuroimage. 12:109–111. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Staudenherz A, Wolfsberg S, Killer M, et
al: Microvessel density is not crucial for scintigraphic
visualization of brain tumors using 99mTc-MIBI. Microvasc Res.
67:218–222. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Nagamachi S, Jinnouchi S, Nabeshima K, et
al: The correlation between 99mTc-MIBI uptake and MIB-1 as a
nuclear proliferation marker in glioma – a comparative study with
201TL. Neuroradiology. 43:1023–1030. 2001.PubMed/NCBI
|
|
19.
|
Ak I, Gulbas Z, Altinel F and Vardareli E:
TC-99m MIBI uptake and its relation to the proliferative potential
of brain tumors. Clin Nucl Med. 28:29–33. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Carvalho PA, Chiu ML, Kronauge JF,
Kawamura M, Jones AG, Holman BL and Piwnica-Worms D: Subcellular
distribution and analysis of technetium-99-MIBI in isolated
perfused rat hearts. J Nucl Med. 33:1516–1522. 1992.PubMed/NCBI
|
|
21.
|
Piwinca-Worms D, Kronauge JF and Chiu ML:
Enhancement by tetraphenylborate of technetium-99m-MIBI uptake
kinetics and accumulation in cultured chick myocardial cells. J
Nucl Med. 32:1992–1999. 1991.PubMed/NCBI
|
|
22.
|
Offersen B, Sorensen F, Yilmaz M, Knoop A
and Overgaard J: Chalkley estimates of angiogenesis in early breast
cancer. Acta Oncol. 41:695–703. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Mineo TC, Ambrogi V, Baldi A, Rabitti C,
Bollero P, Vicenzi B and Tonini G: Prognostic impact of VEGF, CD31,
CD34 and CD105 expression and tumor vessel invasion after radical
surgery for IB-IIA non-small cell lung cancer. J Clin Pathol.
57:591–597. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Beauchesne P and Soler C: Correlation of
99m Tc-MIBI brain spect (Functional index ratios) and survival
after treatment failure in malignant glioma patients. Anticancer
Res. 22:3081–3085. 2002.PubMed/NCBI
|
|
25.
|
Soler C, Beauchesne P, Maatougui K, et al:
Technetium-99msestamibi brain single-photon emission tomography for
detection of recurrent gliomas after radiation therapy. Eur J Nucl
Med. 25:1649–1657. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
San Pedro EC, Yilmaz M, Liu HG, Rosenfeld
SS and Mountz JM: A new semiquantitative method for comparing brain
tumor uptake of Tc-99m sestamibi and TL-201. Clin Nucl Med.
24:868–873. 1999.PubMed/NCBI
|
|
27.
|
Field A: Discovering Statistic Using SPSS.
2nd edition. SAGE; California: 2005
|
|
28.
|
Glantz MJ, Burger PC, Herdon JE II,
Friedman AH, Caircross JG, Vick NA and Shold SC Jr: Influence of
the type of surgery on the histologic diagnosis in patients with
anaplastic gliomas. Neurology. 41:1741–1744. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Aronsson DE and Muhr C: Quantification of
sensitivity of endothelial cell markers for the astrocytoma and
oligodendroglioma tumors. Anticancer Res. 22:343–346.
2002.PubMed/NCBI
|
|
30.
|
Shivakumar S, Prabhakar BT, Jayashree K,
Rajan MG and Salimath BP: Evaluation of serum vascular endothelial
growth factor (VEGF) and microvessel density (MVD) as prognostic
indicators in carcinoma breast. J Cancer Res Clin Oncol.
135:627–636. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Tohama Y, Gratas C, van Meir EG, et al:
Necrogenesis and Fas/APO-1 (CD95) expression in primary (de novo)
and secondary glioblastomas. J Neuropathol Exp Neurol. 57:239–245.
1998.PubMed/NCBI
|
|
32.
|
Homma T, Fukushima T, Vaccarella S, et al:
Correlation among pathology, genotype and patient outcomes in
glioblastoma. J Neuropathol Exp Neurol. 65:846–854. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Netto GC, Bleil CB, Hilbig A and Coutinho
LM: Immunohistochemical evaluation of the microvascular density
through the expression of TGF-β (CD 105/endoglin) and CD 34
receptors and expression of the vascular endothelial growth factor
(VEGF) in oligodendrogliomas. Neuropathology. 28:17–23.
2008.PubMed/NCBI
|
|
34.
|
Vaquero J, Zurita M, Coca S, Oya S and
Morales C: Prognostic significance of clinical and
angiogenesis-related factors in low-grade oligodendrogliomas. Surg
Neurol. 54:229–234. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Ohgaki H and Kleihues P: Population-based
studies on incidence, survival rates and genetic alterations in
astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol.
64:479–489. 2005.PubMed/NCBI
|
|
36.
|
Ohgaki H and Kleihues P: Genetic pathways
to primary and secondary glioblastoma. Am J Pathol. 170:1445–1453.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Folkerth RD: Descriptive analysis and
quantification of angiogenesis in human brain tumors. J Neurooncol.
50:165–172. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Traweek ST, Kandalaft PL, Metha P and
Battifora H: The human hematopoietic progenitor cell antigen (CD34)
in vascular neoplasia. Am J Clin Pathol. 96:25–31. 1991.PubMed/NCBI
|
